CPT 81470: XLID Genomic Sequence Panel (≥60 Genes)
Commercial payers pay $943 on average nationally for this procedure.
CPT code 81470 describes a genomic sequence panel test that analyzes a patient specimen for genetic sequences across at least 60 genes, including 15 genes specifically related to X‑linked intellectual disability disorders; service type: genomic sequencing panel for XLID (molecular diagnostic testing); typical site of service: clinical laboratory or molecular diagnostics laboratory processing patient specimens such as blood or saliva.
Customize your policy alerts
Sign up for cpt 81470 policy alerts
Get alerted when payer policies referencing 81470 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
BUCA’s average commercial rate for CPT 81470 sits near $943, serving as a practical market midpoint. Blue Cross Blue Shield displays the highest mean ($1,100.10) and a wide upper tail (P90 $1,378.20), while Cigna’s mean is $896.30 with a P90 of $1,628.10, indicating a presence of high outliers. Aetna’s mean is lower at $574.90 with a very low P25 ($375.20) and a P75 around $731.20, creating a moderate interquartile spread but a lower central tendency. UnitedHealth Group’s mean is $728.70 with a P25 of $383.90 and P75 of $914.00, placing it between Aetna and BUCA on central tendency.
Assessing dispersion by interquartile range (P75 minus P25): Blue Cross Blue Shield shows a tight IQR of $249.10 ($1,078.40 - $829.90), the narrowest among payers listed, while Cigna’s IQR is $740.30 ($1,207.50 - $470.20), the widest. UnitedHealth Group’s IQR is $530.10 and Aetna’s is $355.00, placing them in the middle of the dispersion spectrum. These differences highlight that price variability across commercial payers ranges from relatively concentrated (Blue Cross Blue Shield) to highly dispersed (Cigna), with BUCA’s mean providing a useful commercial benchmark at $942.90.